TB/FLU-05E
TB/FLU-05E is a mucosal TB vaccine candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing truncated NS1 protein NS1(1–124) and a full-length TB10.4 and HspX proteins of M.tb within an NS1 protein open reading frame. Vaccine formulation: Liquid nasal spray.
Read MoreBCG (Travel vaccine)*
The purpose of this trial (TIPI Trial), is to find out if a single dose of pre-travel vaccination with BCG can lessen tuberculosis (TB) infection by producing an immune response when given to adults traveling to countries with a high burden of TB. BCG (Tokyo 172), supplied by Japan BCG Lab, will be compared with…
Read MoreBCG (Revaccination)*
The Gates MRI BCG ReVax trial is a Phase 2B trial conducted to inform policy. No label change or new indication is intended. The trial compares AJVaccines’ BCG (Danish 1331) to saline placebo for the prevention of sustained IGRA conversion (initial conversion and IGRA-positive 3 and 6 months post initial conversion), as a proxi for…
Read MoreTB/FLU-04L*
Based on the attenuated influenza strain Flu NS106/ESAT-6_Ag85A expressing mycobacterial antigens Esat-6 and Ag85A.
Read MoreTB/FLU-01L*
Replication-deficient recombinant influenza virus A expressing ESAT-6 antigen.
Read More